Array BioPharma will soon be entering a pivotal trial for its wholly owned blood cancer drug and investors should know its outlook by the end of 2014, says the company's CEO Ron Squarer. Array is also partnering with AstraZeneca and Novartis on a number of other cancer drugs with trials soon getting underway that could transform the company by year end. Squarer says Array is superior at smaller, faster hematology studies, while partnerships work better for larger projects, and he is not giving away the store when teaming up with the likes of Celgene.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

If you liked this article you might like

STMicroelectronics, Intercept Pharmaceuticals: 'Mad Money' Lightning Round

Watch Out For the Dominoes That Fall: Cramer's 'Mad Money' Recap (Wed 9/20/17)

Mirati Skyrockets On Positive Data - Biotech Movers

Array BioPharma Seems to Be in a New Uptrend